Kandalaft lab
We work on the clinical development of personalized cancer vaccines. The aim is to improve whole tumor lysate vaccination approaches and other personalized cancer vaccine approaches by improving the dendritic cell platform and by choosing the most immunogenic antigen with the most practical preparation to be translated rapidly to the clinic. The other focus of our lab is to find the best setting to integrate vaccines in the standard of care treatment plan for ovarian cancer patients and to understand the immune fitness of cancer patients and correlate it with vaccination. ...
Research projects
Prof. Lana Kandalaft directs the Center of Experimental Therapeutics (CTE), which supports the advancement of innovative therapies by ensuring the most efficient transition of new treatments and care techniques from the laboratory to the patient.
Latest publications
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Pétremand R, Chiffelle J, Bobisse S, (...), Coukos G, Zoete V, Harari A
Nat Biotechnol – 2024 May 7
PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.
Morotti M, Grimm AJ, Hope HC, (...), Böttcher JP, Dangaj Laniti D, Coukos G
Nature – 2024 Apr 24
Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides.
Ferreira HJ, Stevenson BJ, Pak H, (...), Nesvizhskii AI, Müller M, Bassani-Sternberg M
Nature communications – 2024 Mar 15
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma.
Barras D, Ghisoni E, Chiffelle J, (...), Harari A, Laniti DD, Coukos G
Science immunology – 2024 Feb 2
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S, Bianchi V, Tanyi JL, (...), Kandalaft LE, Harari A, Coukos G
Nature Cancer – 2023 Sep 21
Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development.
Kreidieh FY, Tawbi HA, Alexaki A, Borghaei H, Kandalaft LE
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting – 2023 Jun
The current clinical landscape of personalized cancer vaccines.
Fritah H, Rovelli R, Chiang CL, Kandalaft LE
Cancer treatment reviews – 2022 May 1
Team
Lana Kandalaft
PhD Associate Professor, Cancer vaccine development, Department of Oncology, Director of Center of experimental therapeutics UNIL & CHUV, Ludwig adjunct scientist, Ludwig Institute for Cancer Research Lausanne
lana.kandalaft@chuv.chOther members
Selected Publications
The current clinical landscape of personalized cancer vaccines.
Fritah H, Rovelli R, Chiang CL, Kandalaft LE
Cancer treatment reviews – 2022 May 1
Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers.
Kandalaft LE, Harari A
Cancers – 2021 Nov 19
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.
Chiang CL, Rovelli R, Sarivalasis A, Kandalaft LE
Cancers – 2021 Sep 10
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Tanyi JL, Chiang CL, Chiffelle J, (...), Coukos G, Harari A, Kandalaft LE
NPJ vaccines – 2021 Mar 15
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
Dafni U, Martín-Lluesma S, Balint K, (...), Zaman K, Sarivalasis A, Kandalaft LE
European journal of cancer (Oxford, England : 1990) – 2020 Nov 19
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon PO, Harari A, Auger A, (...), Demartines N, Coukos G, Kandalaft LE
Cytotherapy – 2020 Oct 14
Editorial overview: Pharmaceutical biotechnology: new frontiers in cancer immunotherapy.
Kandalaft LE, Graciotti M
Current opinion in biotechnology – 2020 Sep 8
Antitumour dendritic cell vaccination in a priming and boosting approach.
Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE
Nature reviews. Drug discovery – 2020 Aug 6
Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting.
Iancu EM, Kandalaft LE
Current opinion in biotechnology – 2020 Jul 11
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B, Sarivalasis A, Lozano LE, (...), Romero P, Viganó S, Kandalaft LE
European journal of cancer (Oxford, England : 1990) – 2020 Jun 23
Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
Martin-Lluesma S, Graciotti M, Grimm AJ, (...), Boudousquié C, Chiang CL, Kandalaft LE
Current opinion in biotechnology – 2020 Apr 22
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
Chiang CL, Kandalaft LE, Tanyi J, (...), Powell DJ Jr, Mick R, Coukos G
Clinical cancer research : an official journal of the American Association for Cancer Research – 2013 Jul 9
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.
Kandalaft LE, Chiang CL, Tanyi J, (...), Balint K, Mick R, Coukos G
Journal of translational medicine – 2013 Jun 18
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.
Kandalaft LE, Powell DJ Jr, Chiang CL, (...), Torigian DA, June CH, Coukos G
Oncoimmunology – 2013 Jan 1
Related news
Events
AGORA Sustainability Day
Events
Invitation Public PhD Thesis Defense – Hajer Fritah, Kandalaft lab
Events
